Spike Protein News and Research

RSS

Combination of prior infection and vaccination produces a more potent defense against SARS-CoV-2

Antibodies against the SARS-CoV-2 spike protein produced by the immune system can help identify and fend off future infections, but not all antibodies are the same.

7 Dec 2021

Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant

The current study not only analyses the mutations in the Omicron spike variant but classifies various combinations of spike mutations into groups.

7 Dec 2021

Exploring SARS-CoV-2 vaccine responsiveness in immunosuppressed patients

A new study indicates an immunological response to SARS-CoV-2 vaccines in immunosuppressed patients that were comparable to healthy patients.

7 Dec 2021

Impact of post-translational modifications in the pathogenicity of SARS-CoV-2

A new study provides understanding of the intricate roles and functions of the different elements of spike proteins and shows how the spike protein samples a crowded surface of its host cell via the glycans.

7 Dec 2021

Community transmission of SARS-CoV-2 lineage with novel mutations in Florida

A new study describes the introduction and spread of a SARS-CoV-2 lineage, A.2.5 in Florida using samples from the Florida Department of Health (FDOH) Bureau of Public Health Laboratories (BPHL).

7 Dec 2021

Study suggests algal polysaccharide may be a promising anti-COVID-19 candidate

Researchers from the Rensselaer Polytechnic Institute have been investigating the potential of rhamnan sulfate as an antiviral agent.

7 Dec 2021

COVID-19 severity is correlated with T cell receptor repertoire signatures

In a new study published in the bioRxiv* preprint server, researchers found that specific TCR sequences predicted the severity of coronavirus disease 2019 (COVID-19) infection. Additionally, there was evidence of increased CDR3 sequences and changes in k-mer motifs for patients with severe illness.

6 Dec 2021

Omicron variant increases risk of SARS-CoV-2 reinfection

New surveillance data from South Africa published in the medRxiv* preprint server suggests that the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omnicron variant has the potential to escape naturally-acquired immunity. The research indicates people who previously recovered from a coronavirus disease 2019 (COVID-19) are at risk for reinfection with the Omicron variant. The results show that the risk of reinfection is greater with the Omicron variant versus Delta and Beta.

6 Dec 2021

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

A new mouse model suggests that prior HCoV-OC43 S immunity primes neutralising antibody responses to otherwise subimmunogenic SARS-CoV-2 S exposure as well as promotes S2-targeting antibody responses.

6 Dec 2021

Study shows COVID booster shots work

A new study investigates uses seven different COVID-19 vaccines as the third dose to boost immunity in vulnerable patients.

6 Dec 2021

Safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine

Researchers have presented the results of phase 1 and phase 2 clinical trials of a SARS-CoV-2 recombinant spike protein vaccine (Abdala).

6 Dec 2021

SARS-CoV-2 immune memory in mRNA vaccine recipients

Researchers measured SARS-CoV-2–specific antibody, memory B cell, and memory T cell responses in a group of healthy subjects who generated primary immune responses to two doses of mRNA vaccine compared to a group of SARS-CoV-2–recovered vaccines.

6 Dec 2021

Forecasting outbreak of SARS-CoV-2 Omicron variant with Tajima's D

A new study argues that that rapid genomic sequence surveillance is absolutely crucial and Tajima D tests should be included to predict future COVID-19 outbreaks.

6 Dec 2021

Announcing the Winners of The Scientist’s Top 10 Innovations of 2021

Each year The Scientist seeks to highlight the latest and greatest tools, technologies, and techniques to hit the life science landscape.

From Resolve Biosciences 6 Dec 2021

Sino Biological Launches A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)

Sino Biological, Inc. (https://www.sinobiological.com; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus

From Sino Biological Inc. 6 Dec 2021

Scientists identify molecular features of antibody responses to SARS-CoV-2 spike

New study identifies diverse molecular features of public antibody responses to SARS-CoV-2 spike protein.

5 Dec 2021

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination

A new study supports the hypothesis that heterologous vaccination can provide an increased immune response against virus infection, supporting several other studies that have indicated similar events.

5 Dec 2021